CYBERDYNE

Consolidated Financial Result Briefing for the fiscal year ended March 31, 2024

CYBERDYNE, Inc.
May 15, 2024

Consolidated financial statements

FY2024 - Consolidated Results Summary (IFRS)

(Unit : Millions of yen)

	FY2022	FY2023	+/-	YoY
Revenue	3,289	4,354	+1,065	+32.4%
Operating profit	-1,145	-2,018	-873	—
Profit before tax	53	-1,141	-1,194	—
Profit attributable to owners of parent	-298	-1,476	-1,178	—
EBITDA ☆	-1,005	-1,177	-172	—

Revenue

4,354 Million
YoY +1,065 million（+32%）

- Increase from rental outside Japan　+121 Million
- Increase from treatment service in US RISE Group etc. +361 Million
- Increase from acquisition of new business area such as German mobility company　+582 Million

Operating profit

-2,018 Million
YoY -873 Million

- Increase from rental　+137 Million
- Initial investment in U.S. and European subsidiaries -350 Million
- One-time losses due to impairment of good will -660 Million

* **Operating profit without this one-time losses**
-1,358 Million
YoY -213 Million

Profit before tax

-1,141 Million
YoY -1,194 Million

- Increase of operating loss　-873 Million
- Finance income/expenses and gain/loss related to CEJ Fund　-321 Million
  (FY23 877M - FY22 1,198M = -321M

☆ EBITDA = Operating profit ＋ Depreciation and amortization ± Other income and expenses

Consolidated financial results (IFRS)
Performance trends

【Q4 results】Sales +24% (QoQ comparison)

(Unit : Millions of Yen)

	FY2022	FY2023					Quarter on Quarter		Year on Year	
	Q4	Q1	Q2	Q3	Q4	Q1-Q4	+/-	+/- %	+/-	+/- %
Revenue	915	1,045	1,058	1,115	1,135	4,354	+20	+1.8%	+220	+24.0%
Cost of sales	440	480	480	517	484	1,961	-33	-6.3%	+44	+10.1%
Gross profit	475	566	579	598	651	2,393	+53	+8.8%	+176	+37.0%
R&D Expenses	241	174	180	163	360	877	+197	+120.9%	+119	+49.6%
Other SG&A	757	766	757	771	958	3,251	+187	+24.3%	+201	+26.5%
Other income/ expenses	127	67	-651	49	252	-282	+203	+411.2%	+125	+98.4%
Operating profit	-396	-308	-1,008	-287	-415	-2,018	-129	-	-19	-
Finance income/ expenses	434	363	-12	-106	-184	61	-78	-	-618	-142.4%
Other	-97	712	74	6	24	816	+18	+272.6%	+121	-
Profit before tax	-59	767	-947	-386	-575	-1,141	-189	-	-516	-
Profit attributable to owner of the parent	-366	330	-933	-349	-525	-1,476	-176	-	-159	-
EBITDA	-488	-212	-194	-177	-595	-1,177	-418	-	-107	-

Consolidated financial results: Revenue/Operating profit (Margin)

Operating profit from rental of products 818 Million (Operating profit margin 46%)

(Unit : Millions of Yen)

		FY2022 Q1-Q4	FY2023 Q1-Q4	+/-	+/- %
Product rental	Revenue	1,640	1,762	+121	+7%
	Operating profit ☆ (Margin)	744 (45%)	818 (46%)	+74	+10%
Treatment service	Revenue	1,285	1,646	+361	+28%
	Operating profit ☆ (Margin)	-310 (-24%)	-552 (-34%)	-242	-
New business expansion	Revenue	364	946	+582	+160%
	Operating profit ☆ (Margin)	-161 (-44%)	-197 (-21%)	-35	-
RD expenses and Head office expenses ☆☆	Adjusted amount	-1,418	-2,087	-670	-
Consolidated total (IFRS)	Revenue	3,289	4,354	+1,065	+32%
	Operating profit (Margin)	-1,145 (-35%)	-2,018 (-46%)	-873	-

☆ Operating income by business segment is the amount of profit or loss, which is revenue minus operating expenses, for each business.

☆☆ RD expenses and head office expenses, are adjustment amount of R&D expenses, head office administrative expenses, other income and expenses, etc.

Without one-time expense of (660M), -1,427M

- Rental of product: Rental income from the Group's product (include income from sold products)
- Treatment service: Income from treatment at the Group's rehabilitation facilities (including Robocare)
- New business expansion: Revenue from new business area of the Group (subsidiary company in mobility and sleep apps)

Rental revenue by each products

Overseas product rental sales increased by 190M YoY (+30%)

Usage	Product classification	Japan	Outside Japan	Total
Cybernics Treatment (Functional improvement/ regeneration)	HAL Lower Limb Type (Medical)	333 (325)	517 (369) +40%	**850 (694)**
	HAL Lower Limb Type (non-medical)	163 (179)	-	**163 (179)**
	HAL Single Joint Type	90 (116)	100 (82)	**190 (198)**
Care and for well-being	HAL Lumbar Type for Well-being	114 (162)	95 (113)	**209 (275)**
Labor Support	HAL Lumbar Type for Labor Support	46 (65)	-	**46 (65)**
	Mobility Robot (CL02 etc.)	139 (89)	-	**139 (89)**
Other (Acoustic X and other products)		60 (78)	103 (62)	**164 (140)**
Total		**946 (1,015)**	**816 (626)** +30%	**1,762 (1,640)**

(Unit : Millions of Yen)

Top : FY2023 Q1-Q4
(Bottom : FY2022 Q1-Q4)

Consolidated financial results (IFRS) by geographical region

Significant increase of oversea sale +1,155M (53% to 67% of total revenue)



FY2022 Q1-Q4



FY2023 Q1-Q4

Americas: North, Central and South America
EMEA : Europe, the Middle East and Africa
APAC : Asia-Pacific * Revenue from Japan is stated separately

Ref) Consolidated financial results (IFRS) by geographical regions and type of transaction

Significant increase in overseas revenue from each type of transaction

(Unit : Millions of Yen)

FY2023 Q1-Q4 (FY2022 - Q1-Q4)	Japan	Americas	EMEA	APAC	**Total**
Rental of products	946 (1,015) -7%	68 (51) +34%	280 (205) +36%	468 (370) +27%	**1,762** **(1,640)** +7%
Treatment service	137 (169) -19%	1,453 (1,051) +38%	55 (65) -14%	-	**1,646** **(1,285)** +28%
New businesses	373 (364) +3%	-	573 (-)	-	**946** **(364)** +160%
Total	**1,457** **(1,547)** -6%	**1,521** **(1,102)** +38%	**908** **(270)** +236%	**468** **(370)** +27%	**4,354** **(3,289)** +32%

Outline of the business

Realization of Techno-peer Support Society

A future society where people and technology coexists, cooperates and mutually support each other

For wide variety of people faced with health, physical function, cognitive and psychological problems
A safe and secure society (well-being society) where people of all generations can increase their independence, freedom and solve various problems in their lives



→ Create “Cybernics Industry”, a new industry that follows Robot and IT Industry

Cybernics Technology: Innovative core technology of Cybernics Industry

Cybernics: Fuses and combines humans, AI-Robots and Information Systems



***Cybernics:** Science and technology in cutting-edge areas that combine different fields such as brain/neuroscience, physiology, artificial intelligence (AI), robotics, information technology (IT), psychology, economy and innovation with a focus on Human, AI-robots and Information Systems to realize the fusion of bio/medical technologies and AI, robotics and information technologies.

(Reference)
The Cabinet Office's FIRST, ImPACT, and SIP programs address Cybernics as pioneering cutting-edge innovative science and technology areas

Business in the integrated space of “Human” + “Cyber/Physical Space”

Improving the well-being of seniors and people with disability

Improving the well-being through supporting and supervising solutions

Towards the 5th Industrial Revolutions!

“Human”+”Cyber/Physical Space”

HCPS Fusion Technology

Cybernics Industry

that will follow Robot and IT Industry



Prevention, early detection and medical/healthcare



Work support and improving efficiency through AI automation

【Medical】Global Dissemination of Cybernics Treatment

Motion principle of Cybernics Treatment Technology

Wearable Cyborg HAL : Cybernics Treatment that induces functional regeneration

Signals from a person's brain nerve system are processed by signal processing and artificial intelligence in real-time, HAL moves as if it were a part of the person's own body according to the person's intention





1) HAL obtains information related to the brain nerve and muscles from the peripheral part of the body
2) HAL synchronizes with the wearer's intentions and functions according to the intention
3) Forms an interactive bio-feedback loop to induce improvement in the body-nerve and muscles systems, achieving the goal of the Cybernics Treatment

【Medical】Insurance reimbursement for Cybernics Treatment

Increased insurance points after confirming safety and efficacy during 5 years of post-marketing surveillance

✦Excerpts from the Proposal to Evaluate the Medical Technology (why it should be reevaluated) submitted by the Japanese Society of Neurological Therapeutics – Translated by CYBERDYNE

"During 5 years of post-marketing surveillance, the medical technology produced significant improvement of physical function towards slowly progressive neuromuscular disease, **which are intractable diseases with no established treatment methods that are effective**. The medical effect observed was unheard of by any existing treatment methods, including pharmaceuticals approved for these diseases. Due to the progressive nature of these intractable diseases, research on the natural course of the disease suggest a gradual decline of motor functions. However, when this medical technology was utilized repeatedly over a long duration of 3.5 years, an opposite trend was suggested, and motor function was maintained/improved. Furthermore, the medical technology did not increase the destruction of the patient's muscles. **The CK value in the blood** was actually in the declining trend, which is medically noteworthy**. **Thus, it was suggested that medical technology is a safe treatment method for progressive neuromuscular patients**. The medical technology should no longer be regarded as a treatment method to support gait exercises. It should be reevaluated as a **new treatment method to activate the loop** of the patient's brain-nerve systems."

Added to items not covered by the DPC comprehensive evaluation (items calculated at piece rate)!

Increased reimbursement points (40,000 yen for the first 9 sessions and 20,000 yen for the following sessions) are realized!

【Medical】Cybernics Treatment (functional improvement/rehabilitation treatment)

Cybernics Treatment: Developed as innovative method utilizing HAL for treating brain-nerve-musculoskeletal disorders

HAL Lumbar Type

HAL Single Joint Type

HAL Lower Limb Type

*The treatment services operated by the Group are classified as “service sales” and “rental sales” in cases where products are rented based on rental contract

Global dissemination of Cybernics and reinforcing collaboration ①

INTERNATIONAL CONFERENCE on CYBERNICS HAL 2023

2023.10.13 Kuala Lumpur Malaysia

Strengthening international collaboration by bringing together clinicians, researchers, and other experts from around the world who work with Cybernics

Global dissemination of Cybernics and reinforcing collaboration ②

2024.1.12 Hannover Germany

Cybernics & Neurobionics Summit 2024 (Jointly hosted by International Neuroscience Institute)

Gathering the world's leading pioneers in cutting-edge developments in Cybernics and neurobionics

Joint hosts
Dr. Madjid Samii (center) - Founder of INI, President of INI
Dr. Amir Samii (right) - Vice President of INI

Progress of approval by the U.S. FDA

US FDA becomes to first to clear HAL Small Model and Cerebral Palsy (2024/5/7)

*Above 12 years old



Conventional model

Small Model

Use image of HAL Small Model*

*Product used in this image differs from the medical version

Development pipeline (1)

1）Medical HAL (Lower Limb Type) : Clinical trials etc.

As of May 15 2024



Development pipeline (2)

2）Medical HAL (Lumbar Type)：Clinical trials etc.

As of May 15 2024

Target disease	Product Development	Clinical Trial (Exploratory)	Clinical Trial (Validation)	Application/ examination	Approval (public health insurance in Japan)	Marketing (Post-marketing surveillance)	Public health insurance	Current status
Parkinsons Disease								Currently designing a protocol for clinical trials while confirming efficacy through pilot studies

*Topics：Started working on parkinsons disease, a disease with over nine million patients world wide

3）Medical HAL (Single Joint Type)

As of May 15 2024

Target disease	Product Development	Clinical Trial (Exploratory)	Clinical Trial (Validation)	Application/ examination	Approval (public health insurance in Japan)	Marketing (Post-marketing surveillance)	Public health insurance	Current status
Brain-nerve (e.g. stroke)							Public Health Insurance	Equipment for increasing exercise load Planning for insurance reimbursement Planning for insurance reimbursement
Orthopedics (e.g.Post knee joint replacement)								Planning for insurance reimbursement Planning for insurance reimbursement Planning for insurance reimbursement

Medical device approval for Medical HAL Lower Limb Type

Expansion of cleared diseases in USA (Disease/Size)

As of May 15, 2024

		Stroke	Spinal Cord Injury	Neuromuscular Disease*	Other diseases	Small size
Japan		(Preparing for additional trial)	(Communicating with regulators)	Approved	• HTLV-1 Associated Myelopathy (HAM) • Hereditary spastic paraplegia	(application in progress)
USA		Approved	Approved	Approved	• Cerebral palsy • HTLV-1 Associated Myelopathy (HAM) • Hereditary spastic paraplegia	Approved
EMEA	Europe	Approved	Approved	Approved		(application in progress)
	Türkiye	Approved	Approved	Approved		
	Saudi Arabia	Approved	Approved	Approved		
APAC	Malaysia	Approved	Approved	Approved		
	Indonesia	Approved	Approved	Approved		
	Thailand	Approved	Approved	Approved		
	Singapore	Approved	Approved	Approved		
	India	Approved	Approved	Approved		
	Taiwan	(application in progress)	Approved	(application in progress)		
	Australia	Approved	Approved	Approved		

*Spinal muscular atrophy, spinal and bulbar muscular atrophy, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, distal muscular dystrophy, inclusion body myositis, congenital myopathy, muscular dystrophy

Global dissemination of Medical HAL/Cybernics Treatment

Available in over 20 countries and regions

Cyberdyne Care Robotics
(Germany)

CYBERDYNE HQ

EMEA Base
Cyberdyne Care Robotics GmbH (Germany)

Cooperselios
(Italy)

PERKESO – REHABILITATION CENTRE MELALA
(Malaysia)

APAC Base
CYBERDYNE MALAYSIA SDN. BHD.

Singapore General Hospital
(Singapore)

Brooks Rehabilitation
(US Florida)

RISE Healthcare Group
(USA California)

Americas Base
CYBERDYNE USA INC.

EMEA : Europe, Middle East and Africa

Social implementation of Cybernics Treatment (USA)

Development of Cybernics Treatment through Rise Healthcare

RHG POWERED BY CYBERDYNE

- ✦ **Strong business in LA・San Diego**
- ✦ **Commenced fee-based service from 2023 (out-of-pocket+insurance hybrid treatment)**
- ✦ **No. treatment sessions increased 2.4 times, even though fee-based service started***
- ✦ **Top3 users are stroke, Parkinson's disease and spinal cord injury patients**
- ✦ **76% referred by doctors/patient-to-patient/ patient associations**

*Performance from January to December

Accelerate business further in light of approval of HAL small model, and expansion of indications for cerebral palsy, etc.

Social implementation of Cybernics Treatment (Malaysia)

Collaboration with Malaysian government-affiliated organizations to promote Cybernics Treatment

2018.11
Social Security Organization (PERKESO) started utilization of HAL

2019.5
Opened APAC's first Cybernics Treatment Center

2019.8
Strengthening ties with the Malaysian government
Business alliance with PERKESO

2022.2
Established Malaysian subsidiary CYBERDYNE MALAYSIA SDN. BHD.

2022.6
PERKESO announces construction of PERKESO National Neuro-Robotis and Cybernics Centre

End of 2024(schedule)
Completion of PERKESO National Neuro-Robotis and Cybernics Centre

HAL rented units
As of March 2024

72
92
106
114 units

FY18 FY19 FY20 FY21 FY22 FY23 FY24

Social implementation of Cybernics Treatment (Malaysia)

Provides Cybernics Treatment free for patients due to Public Social Compensation Insurance

SOCSO/PERKESO (Malaysia Public Social Security Organization)

SOCSO has four functions: disability pension, survivor's pension, medical coverage and occupational injury coverage, and is compulsory for Malaysian and foreign workers in Malaysia to join the program. It provides medical compensation, disability compensation, funeral benefits, child support and nursing care benefits for illness or injury that occurs while commuting to and from work.

Facilities with HAL (12 facilities)



SOCSO Rehabilitation Center

Socso urged to build three new rehabilitation centres in five years

Bernama
15/01/2024 16:00 MYT

KESUMA Minister Urges Nationwide Expansion of SOCSO Rehabilitation Centers

https://www.astroawani.com/berita-malaysia/socso-urged-build-three-new-rehabilitation-centres-five-years-454129

Social implementation of Cybernics Treatment (Malaysia)

The National Center for Neuro-Robotics and Cybernics, the largest medical complex in Southeast Asia

PERKESO National Neuro-Robotic and Cybernics Centre

- ✓Construction underway in Ipoh, Perak, Northern part of Malaysia (Scheduled by the end of 2024)
- ✓First phase project
  - ✓15.6 Hectare (Approx. 3.4 baseball stadiums)
  - ✓Gross floor area is approximately 86,400 square meters
- ✓Capable of accommodating 700 patients at any given time

Strategic base for social implementation of Cybernics Industry, such as HAL, Cybernics Products and technologies of other companies that CYBERDYNE invests through C-Startup

https://www.perkeso.gov.my/images/kenyataan_media/2023/190203_-_LAWATAN_MENTERI_SUMBER_MANUSIA_KE_TAPAK_PUSAT_REHABILITASI_PERKESO_PERAK.pdf?TSPD_101_R0=08e2dacd5fab2000f93a5be67765406ad4c598e4e5aedac205dcd286f8c106bc77d7648842ded7a008048fa483143000fbc3f707cd511bf1367c7352c9e10251d84d1723291abc11ccb8adcffc6ab4640a6f84d8e56752b87e7c10ac4d5baf7b

Spinal Cord Injury: Clinical Trials by German Insurance Authorities

Clinical trials to be conducted on the premise of German public medical insurance coverage

G-BA (German Federal Joint Committee) decides to conduct clinical trials under the premise of insurance coverage

G-BA approves Cybernics Treatment as the standard of care to be considered for spinal cord injury patients (in accordance with §137eSGB V of the Study Regulations)

G-BA itself decides to conduct a clinical trial (the clinical trial will be covered by public health insurance for Cybernics Treatment in advance).

The results of the clinical trial are expected to be included in the German public medical insurance system.

G-BA Preparing Protocol for Clinical Trials

2023/01 Protocol outline presented

2023/03 Expert hearing held

2023/09 Protocol guideline announced → **Commenced selection of CRO on March 2024**

G-BA (Federal Joint Committee): Organization at the federal level that determines basic benefits, prices, standards, etc. for German insurance treatment.
§137e SGB V (Trial Regulation): A system under which the G-BA conducts its own initiated clinical trials and makes final evaluations of promising treatments that could become the standard of care.

Social implementation of Cybernics Treatment (Italy)

Promoting “Scientific Evidence-Based Rehabilitation Model”

Utilizing 25 units of HAL for treatment of approximately 1,000 stroke and spinal cord injury patients

coopselios
prendersi cura, di persona

✓Social cooperative association established on 1984
✓Service in medical, care and education fields
✓Provides service to approximately 6,500 people daily in 8 areas of Italy
✓Over 3,000 professionals

2walk
Italian Cybernic Center

Key points of collaboration

- ✦ Operates Italian Cybernic Center - Second walk (Within Italy)
- ✦ Cooperation for public health insurance reimbursement in Italy
- ✦ Utilization of Coopselios Network in Asia, Middle East, South America and Africa

Healthcare and labor support

【Healthcare】 Neuro HALFIT (Functional Improvement Program)

Program to improve brain-nerve-musculoskeltal function at Robocare Center

HAL Lumbar Type



HAL Single Joint Type

HAL Lower Limb Type

Medical Healthcare Service for Individuals:Neuro HALFIT at Home

Expansion of remote services connecting home and hospitals/facilities through cloud computing

【Integrated Cybernics System】



Robocare Center: Nationwide expansion of *Neuro HALFIT*

Expansion of hubs in the medical healthcare service business for individuals

Available in 18 locations nationwide

【Healthcare】HAL Lumbar Type care prevention program

Significant improvement in mobility functions (daily activities such as standing, walking, running, sitting) of the elderly

Care prevention program (Kanagawa Mirai MIBYO Cohort Study)

Interim evaluation results of short-term intervention twice a week for a total of 10 sessions

Evaluation item	Before HAL Mean (95%CI)	After HAL Mean (95%CI)	Improvement rate	P-value
10m walk (walking speed m/sec)	1.05 (0.98, 1.12)	1.43 (1.35, 1.51)	36%	<0.001***
Locomotiv 5 check *Signs of motor unit deterioration	8.5 (7.7, 9.3)	4.4 (3.3, 5.4)	93%	<0.001***

Recruited N=80 people Out of which, Participants N=79, (Average 75yo, : Intervention group 40 (one drop-out) , Control group 39 (one drop out)

【Healthcare】※ Neuro HALFIT at Home ※ (for individuals in daily lives)

Functional improvement program at home (expands home visit services)



Use image of Neuro HALFIT at Home

HAL is data-linked with the Cyberdyne Cloud, which visualizes biopotential signals that command body movements and posture information, etc. This system enables the wearer to obtain visual feedback and allows the trains to customize a program for each user based on the results of data analysis

*The Home programs are classified as “service sales” and “rental sales” in cases where products are rented based on rental contract

【Labor Support】HAL Lumbar Type

New HAL Lumbar will be announced soon, making the device light weighted and thinner

Lightest Active type device	• Can be worn for long hours • **Became even lighter (2.7kg)**
Slim design (back free)	• Can be worn together with safety belts (full body) and air-conditioned clothes • **Can drive cars while wearing it**
Assist walk	• Can move smoothly to the required venue
Can move around in crouching posture	• Assists various practical movements
IoH/IoT device	• Visualize workload analysis and operating status! integrated production management
Wearable Cyborg	• It moves according to the wearer's intention
Puts on in 10 seconds	• Easy to put on and take off, share with multiple people!
Water/dustproof (IEC reg IP54)	• Can be worn outdoors, even in the rain! (New model is also waterproof)

Lighter !
Thinner !

Construction sites, airports, and distribution warehouses etc.

Integrated Cybernics System



【Workplace】Disinfection/Cleaning Robot CL02

Make office buildings smarter and reduce management costs with advanced technology
Can also be linked with building OS! (Also considering collaboration with major industry players)

Extensive Cleaning ability

- **High-speed autonomous navigation** (Can safely clean at 4km/h to cover massive space in a short time
- **Massive cleaning area** (Detects wall that is 30m away and covers max 3,000m² with full charge battery)
- **High vacuum performance** (One of the best in the industry)

Can be used for multiple tasks such as disinfection

- **Disinfection agent sprayer** (Disinfects handrails and benches)
- **UV Ray Disinfector** (Set on the bottom of the robot to disinfect floors)
- **Wiper cleaner** (Small sound as it does not use vacuum)
- **Carpet spray & Brushing** (Make carpet long lasting)

Visualizes assigned tasks

- **Dust distribution map** (visualizes result of the task)
- **Navigated route** (to create efficient and effective cleaning plan)

Automatically rides on the elevator

- **Elevator interface unit developed inhouse**
  (Can connect to elevators developed by multiple vendors)
- **Can work on multiple floors** (Expands the space that can be cleaned)

Cloud linkage

- **“CYCLES” designed for the Robot** (realizes high usability and management)
- **Integration with the base system**



Strategy for growth

Image of growth scenario: Strengthen development areas and business strategies



Reinforcing existing business, pioneering new field
(evolution of the business model, **M&A**)

Expanding existing business
(expanding usage, business towards **individual users**, etc.)

Developing the business base
(**Expanding product lineup,** obtaining **regulatory approvals** in each countries)

HCPS fusion technology：Cybernics/Human cooperative robotics

As a commitment to science, technology and innovation, CYBERDYNE participated in the Cabinet Office Strategic Innovation Creation Program (SIP) to strengthen growth strategies



1) Application to various living spaces such as houses, facilities, workplaces, etc.
2) Utilization of HCPS fusion master/remote control technology (Cybernic master/remote technology) integrated with human information (physiology, body, behavioral cognition, psychology, etc.)
3) Non-invasive acquisition and utilization of human information through HCPS fusion human collaborative robotics
4) Linking with other related technologies to improve the independence and freedom of seniors and people with mobility problems

Source: Cabinet Strategic Innovation Program (SIP), Secretariat of Science, Technology and Innovation, Cabinet Office, Government of Japan, “Development of Fundamental Technologies and Rules for Expanding Human-Coordinated Robotics: Strategy and R&D Plan for Social Implementation,” Pg 5.

Future of medical healthcare and healthy life
Prevention/pre-symptomatic, medicine, rehabilitation/long-term care

Medical/Healthcare/Healthy life

Pre-Hospital
Early medical・life period Prevent/pre-symptomatic

Hospital
Diagnose, treat, inpatient/outpatient

Post-Hospital
Late medical・life period : rehab/long-term care

early medical・life period

Acute

Recovery

Late medical・life period

Household・work place・life space

Household・work place・life space



Close coordination, fusion between medical and non-medical field to evolve into comprehensive initiatives

【Prevention and early detection】Ultra small vital sensor Cyvis

Healthcare monitoring on daily basis with Cyvis

Daily accumulation, analysis, and AI processing of various vital data

- **Cardiac activity**
- **brain activity**
- **body temperature**
- **Body movements**
- **Breathing / SpO2 (optional)**



Check for arrhythmia and atrial fibrillation
to prevent myocardial infarction and cerebral infarction
Option to check breathing conditions during sleep for early detection of sleep apnea risk

✅ **Developed “Cyvis-2” after trial of “Cyvis-1”**
✅ **“Cyvis-2” submitted medical device application on Apr. 2024 and schedules to commercialize on summer to autumn 2024**

【Prevention and early detection】Ultra small vital sensor Cyvis

Expands remote service that connects households to hospitals and facilities



Cybernics Medical Healthcare System

Prevent, early detect and improve on daily basis (data linkage with Cyberdyne Cloud)

Cybernics Medical Healthcare System
that prevent, early detect and improve on daily basis
Hospital, Facility, House, Workplaces

Cyberdyne Cloud
with innovative Cybernics System

Cybernics Treatment and monitoring at hospitals

Health care monitoring in daily life

Improve independence to encourage continuous social activity

Healthcare check and program to improve physical function at home

Cloud Computing

Activity, sleeping check

Sleep Apnea Syndrome, sleep deprivation check

Health Care Monitoring in the Workplace

[Seamless data linkage between hospitals, facilities, homes, and workplaces with IoH/IoT]

【Prevention and early detection】Photoacoustic Imaging Device using LED light array

Contrast-free, non-invasive, real-time, high-resolution 3D imaging

LED array method (patent held by CYBERDYNE)

Adopted as the cover of BioPhotonics, a U.S. industry journal dealing with biophotonics



Peripheral vascular and blood conditions, etc.

Peripheral level examination, which could not be done with conventional imaging equipment, is now possible!

Example of application

- Routine examination and diagnosis of diabetic foot lesions
- Examination of vascular regeneration status by regenerative medicine
- Examination and diagnosis of cancer
- Examination of aging skin, etc.

Currently promoting medical device commercialization as a next-generation medical diagnostic imaging device

【Prevention/early detection】Acoustic X” photoacoustic imaging system with LED light source

Hospitals with Acoustic X: Various hospitals installed the product for clinical researches



C-Startup : Innovation ecosystem to create Cybernics Industry

Cybernics Industry

University and research institutions

Start-ups and entrepreneurs

bio/drug discovery

Med Tech

Big Data

C-Startup

Kringle Pharma
2020/12 listed

CureApp

Rehab

Hirosaki

GAIA BioMedicine

amui

Adria kaim

Allm SHAPING HEALTHCARE
2022/6 M&A

METCELA

Jiksak

KanonCure

PLIMES

Acute Medical Innovation

bitkey

Xenoma

LIFESCAPES

LPIXEL

ANSeeN

regenerative medicine

CYFUSE
2022/12 listed

Technical advices
Financial support
Business support

WHILL

rapyuta robotics

Aillis

IoH/IoT

Cutting-edge technology

Robotics

AI

CYBERDYNE

Medical institutions, care facilities, companies, allied partners

CYBERDYNE

University, research institute, government
WEF Centre for 4th Industrial Revolution,
Consortium of cutting-edge medicine in the 21st century
Smart city council etc,.

CEJ Fund (scale of 10 billion)

CYBERDYNE
大和ハウス工業株式会社
SOMPO 損保ジャパン
DAIDO 大同生命
MIZUHO みずほ銀行
THK
筑波銀行
global brain
MIZUHO みずほキャピタル

2024.3.31 updated

(Ref) Fair value assessment of strategic investment through “C-Startup”

Cumulative investment income 11.4 billion yen vs cumulative investment amount 5.1 billion yen



*Unlisted equity securities are fair valued in accordance with IFRS 9 "Financial Instruments

**OCI (Other Comprehensive Income): Income not recognized in net profit or loss (PL)

(Reference) Investments in which no valuation differences are currently recognized: 6 companies

(As of March 31, 2024)

Cybernics Medical Innovation Base: Outline

Reinforcing CYBERDYNE's growth strategy
Accelerate the fusion of bio- and medical-related technologies with AI, robotics, and information technologies

Innovation center based on Cybernics Technology and regenerative medicine/drug discovery

Kingsky Front Tonomachi, Kawasaki
New base with a view to global expansion
(5 minutes from Haneda Airport)

Life science companies such as C-Startup partners in regenerative medicine and drug discovery move in

New fusion R&D will be promoted!

Cybernics Medical Innovation Base: Purpose

1) Combined Cybernics Treatment : Regenerative Medicine and HAL

While "Cybernics Treatment" using the world's first Wearable Cyborg HAL is becoming a standard treatment for functional improvement and regeneration of human brain nerves and muscles (HAL is already available in 20 countries in Europe, the U.S., Asia, etc.), further therapeutic effects are expected for severe patients by introducing technology at the cellular level and cell-produced substances. The Group will promote the systemization of Cybernics Treatment at this research facility.

2) Combined Cybernics Treatment : Drug and HAL

After the post-marketing study of "Cybernics Treatment" using the Wearable Cyborg HAL, the combination of the latest nucleic acid drugs and HAL has begun in actual medical practice, and synergistic effects from the combined therapy of drugs and HAL are hoped for. CYBERDYNE will promote the systematization of Cybernics Treatment in cooperation with pharmaceutical companies and the institutions occupying such research facilities.

3) Integration of medical and bio-based technologies with AI, robotics, and information systems

In addition to deploying the Group's new-generation robotic bioreactor technologies and technologies that integrate medical/biotechnologies with AI, robotics, and information technologies, the company will provide research facilities to partner companies (medical/biotechnological companies and start-ups that can collaborate with the Company) and others to develop new medical technologies and expand the Company's business.

Disclaimer

This presentation contains forward-looking statements concerning CYBERDYNE, Inc. and its Group's future plans, strategies and performance. Forward-looking statements contained in this presentation are based on information currently available and on certain assumption redeemed rational at the time of creation of this presentation. As such, due to various risks and uncertainties, the statements and assumption does not guarantee future performance, may be considered differently from alternative perspectives and may differ from the actual result.

Further, this presentation contains statements and information regarding corporate entities other than those belonging to the CYBERDYNE group, which have been complied from various publicly- available sources. CYBERDYNE does not verify nor guarantees accuracy and appropriateness of those information.